The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment With Placebo Using Improvement PRAM Score as a Primary Outcome

Conditions: Shortness of Breath, Asthma in Children, Epinephrine Causing Adverse Effects in Therapeutic Use, Salbutamol Adverse Reaction

Sex: All

Ages: 3 Years – 13 Years

Phase: PHASE4

Enrollment: 30

Sponsor: Oman Medical Speciality Board

Summary

Our study aiming to look in improvement of Pediatric Respiratory Assessment Measure (PRAM) score as a primary outcome. The secondary outcomes involving the need for second step management, need for admission and possible side effects.It's double blinded randomized control study comparing Nebulized Epinephrine with standard treatment (salbutamol + Ipratropium) versus the standard treatment only in pediatric patient.A pilot study will be conducted before to detect the sample size required and data will be collected at deferent interval post treatment targeting intension to treat for analysis.

Eligibility Criteria

Inclusion Criteria:Age between 3 and 13 years oldPre-existing diagnosis of asthmaPresenting to the ED with an asthma exacerbationExclusion Criteria:History of chronic lung or upper airway disease other than asthmaHistory significant, uncorrected congenital heart disease or cardiac arrhythmiaImpending respiratory failureAllergy to epinephrine

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05667727). StuddyBuddy aggregates publicly available trial information.